The FREM1 commercial polyclonal antibody blotting pattern was identical to that of the TILRR polyclonal antibody, which detected a 75 KDa peptide with an approximately 4.76- and 9.09-fold reduction in expression in tumor tissues. The gene discussed is FREM1; the disease is neoplasm.